Empagliflozin is a novel hypoglycemic drug by inhibiting the sodium-dependent glucose transporters 2(SGLT2)on the proximal of renal tubules.Studies have shown that empagliflozin reduced the incidence of cardiovascular endpoint events,especially the hospitalization rate and mortality rate diabetes patients combined with reduced ejection fraction heart failure.At present,as a drug for the treatment of cardiovascular diseases(CVD),empagliflozin has attracted more and more attention in clinical practice,but the mechanism of its role in CVD remains unclear.This article mainly focuses on the research progresses of empagliflozin and cardiovascular diseases,such as heart failure,acute myocardial infarction,hypertension and arrhythmia.
维普
万方数据